Chronic Lymphocytic Leukemia

Disease-a-Month

Volumn 58, Issue 4, 2012, Pages 153-167

  Shanshal, Mohammed ^a   Haddad, Rami Y ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; LUMILIXIMAB; MITOXANTRONE; OFATUMUMAB; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; ARTICLE; BLISTER; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER FATIGUE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; ECHOGRAPHY; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; FEVER; GENETIC RISK; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFECTION PREVENTION; LYMPHADENOPATHY; LYMPHOCYTOSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MONOCLONAL B LYMPHOCYTOSIS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NIGHT SWEAT; NONHUMAN; PAPULE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX RATIO; SIDE EFFECT; SKIN NODULE; SKIN ULCER; SPLENECTOMY; SPLENOMEGALY; VIRUS REACTIVATION; WEIGHT REDUCTION;

AGE DISTRIBUTION; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BETA 2-MICROGLOBULIN; BIOPSY, FINE-NEEDLE; BONE MARROW; CHROMOSOME DELETION; CONTINENTAL POPULATION GROUPS; ENVIRONMENTAL EXPOSURE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMANS; IMMUNOGLOBULINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHATIC DISEASES; LYMPHOCYTOSIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SEX DISTRIBUTION; SKIN DISEASES, PAPULOSQUAMOUS; SPLENECTOMY; SPLENOMEGALY; TUMOR VIRUS INFECTIONS; WATCHFUL WAITING;

EID: 84858808471     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2012.01.009     Document Type: Article

References (25)

1. Elter T., Hallek M., Engert A. Fludarabine in chronic lymphocytic leukaemia. Exp Opin Pharmacother 2006, 7(12):1641-1651.
2. Yamamoto J.F., Goodman M.T. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008, 19(4):379-390.
3. Hernández J.A., Land K.J., McKenna R.W. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995, 75(Suppl 1):381-394.
4. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
5. Houlston R.S., Sellick G., Yuille M., et al. Causation of chronic lymphocytic leukemia-insights from familial disease. Leuk Res 2003, 27:871-876.
6. Linet M.S., Devesa S.S., Morgan G.J. The leukemias. Cancer Epidemiology and Prevention 2006, 841-871. Oxford University Press, New York. (3rd ed). D. Schottenfeld, J.F. Fraumeni (Eds.).
7. Agnew K.L., Ruchlemer R., Catovsky D., et al. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004, 150(6):1129.
8. Moulin B., Ronco P.M., Mougenot B., et al. Kidney glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992, 42(1):127-135.
9. Rawstron A.C., Bennett F.L., O'Connor S.J., et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008, 359:575-583.
10. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
11. Zenz T., Benner A., Döhner H., et al. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008, 7:3810-3814.
12. Morris M.J., Tong W.P., Cordon-Cardo C., et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002, (8):679-683.
13. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma. Vol. 2. 2011 Accessed March 28, 2011. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
14. Montillo M., Hamblin T., Hallek M., et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005, 90:391-399.
15. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
16. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
17. Rassenti L.Z., Jain S., Keating M.J., et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112:1923-1930.
18. Eichhorst B.F., Busch R., Stilgenbauer S., et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114(16):3382-3391.
19. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
20. Molica S. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 2007, 48(5):866-869.
21. Lemery S.J., Zhang J., Rothmann M.D., et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010, 16(17):4331-4338.
22. Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1749-1755.
23. Klepfish A., Gilles L., Ioannis K., et al. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions and clinical results in refractory CLL. Ann NY Acad Sci 2009, 1173:865-873.
24. Robak T., Dmoszynska A., Solal-Céligny P., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10):1756-1765.
25. Byrd J.C., et al. Chronic lymphocytic leukemia cyclophosphamide, and rituximab in patients with relapsed or refractory phase 1/2 study of lumiliximab combined with fludarabine. Blood J 2010, 115:489-495.